ClinicalTrials.gov
 Home    Search    Study Topics    Glossary  
 

  Full Text View  
  Tabular View  
  Contacts and Locations  
  No Study Results Posted  
  Related Studies  
The Impact of Stent Deployment Techniques on Clinical Outcomes of Patient Treated With the CYPHER® Stent (S.T.L.L.R.)

This study has been completed.

Sponsored by: Cordis Corporation
Information provided by: Cordis Corporation
ClinicalTrials.gov Identifier: NCT00403338
  Purpose

1500 eligible patients will be treated with the commercially available CYPHER® sirolimus-eluting Bx Velocity™ stent. Patients will be followed to twelve months post-procedure, watching for patients that require a repeat procedure on the same diseased area of the coronary artery.


Condition Intervention Phase
Coronary Stenosis
Device: CYPHER® Bx Velocity™ stent (sirolimus-eluting)
Phase IV

ChemIDplus related topics:   Sirolimus   

U.S. FDA Resources

Study Type:   Observational
Study Design:   Prospective
Official Title:   Prospective Evaluation of the Impact of Stent Deployment Techniques on Clinical Outcomes of Patient Treated With the CYPHER® Stent, The e-CYPHER(SM)S.T.L.L.R., Registry [Study of Deployment Technique on Clinical Results]

Further study details as provided by Cordis Corporation:

Enrollment:   1500
Study Start Date:   December 2004
Study Completion Date:   April 2006

Detailed Description:

Geographical miss has been associated with treatment failures after intracoronary radiation therapy. This phenomenon, which is secondary to vascular injury outside the treated segment, was strongly correlated with the development of restenosis at the edges of the treated coronary segment. The European and Canadian SIRIUS trials (E and C-SIRIUS) randomized 350 patients with similar baseline characteristics of the US SIRIUS study. Operators used shorter post-dilatation balloons and direct stented 27% of the patients, achieving a 4.0% TLR rate and a 5.1% in-lesion binary restenosis. These somewhat superior results support the concept that refinement in deployment techniques may further improve clinical outcomes of drug-eluting stents.

  Eligibility
Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Criteria

Inclusion criteria:

  • Diagnosis of de novo stenosis in major coronary artery
  • Can be treated with stents
  • Candidate for bypass

Exclusion criteria:

  • Recent, severe MI
  • Prior brachytherapy
  • Impaired left ventricle function
  • Heart transplant recipient
  • Impaired renal function
  • Disease in vein grafts from previous bypass
  • Similar treatment within the last 30 days
  Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00403338

Sponsors and Collaborators
Cordis Corporation

Investigators
Study Director:     Robin Boley     Cordis Corporation, a Johnson & Johnson Co.    
  More Information


Publications of Results:

Study ID Numbers:   P03-6323
First Received:   November 22, 2006
Last Updated:   July 8, 2008
ClinicalTrials.gov Identifier:   NCT00403338
Health Authority:   United States: Institutional Review Board

Keywords provided by Cordis Corporation:
myocardial ischemia  
coronary disease  
heart disease  
Coronary Stenosis [MeSH heading: C14.280.647.250.285]  

Study placed in the following topic categories:
Sirolimus
Coronary Disease
Heart Diseases
Myocardial Ischemia
Vascular Diseases
Constriction, Pathologic
Ischemia
Coronary Stenosis

Additional relevant MeSH terms:
Cardiovascular Diseases

ClinicalTrials.gov processed this record on October 03, 2008




Links to all studies - primarily for crawlers